Company
LON:SCLP
Scancell is a clinical stage biotech company developing immunotherapies for a cancer-free future by enhancing long-lasting tumour specific immunity. With deep roots in cancer immunology and translational research, the company aims to translate its innovation and creativity to address the need for fast, potent and accessible therapies that are easy to administer in hard-to-treat cancers.
329 stories · page 6 of 17
In the same announcement, investors were told the company has inked an agreement with an unnamed ‘major European pharmaceuticals company’
It also said no safety concerns emanated from the first group of trial volunteers
The company provided the update alongside its interim results
A glance at some of the day's highlights from the Proactive Investors newswire.
The company's SCIB1 discovery will be used in combination with checkpoint inhibitor drug Keytruda
The pharma group will use the capital raised via the issue of shares and convertible loan notes earlier in the financial year to pursue several clinical programmes
Oxford "is the perfect location for Scancell's expansion, with access to an excellent local talent pool as we grow the business", said CEO Lindy Durrant
Chief executive, Professor Lindy Durrant, said: "The approval of the Modi-1 clinical trial application is a significant achievement for the company.”
It will use technology pioneered by PharmaJet in the COVIDITY phase I clinical trial
Professor Lindy Durrant, who takes the position with immediate effect, previously served as co-CEO of the firm
The two-part study, which is set to get underway sometime in the second half, will look at both safety and immunogenicity – the ability to provoke an immune response
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
“Our next-generation COVID-19 vaccine has the potential to work alongside currently approved vaccines by protecting the population against new variants of SARS-CoV-2," said chief executive, Dr Cliff Holloway
The decision to curtail clinical development work on Scancell target SCIB2 followed a re-assessment of the charity’s collaboration model in the wake of the coronavirus pandemic, the company said
For the six months ended October 31, the developer of immunotherapies said it had ended the period with £25.7mln in cash compared to £3.6mln in April last year, while post-period another £20.5mln had been raised
Companies in the diagnostics, treatment and vaccines space have posted positive news this week
As a second-generation vaccine, Scancell believes SN14 offers several potential advantages over currently approved and late-stage vaccines
"We are excited by the advice and guidance that Gillies and Robert will be able to provide in advancing these trials and look forward to working with them," said CEO Cliff Holloway
The directors said they are aware of a number of shareholders who have indicated that they would vote in favour if more time was available
The company, which has received tremendous support from its shareholders, expects to make further progress in the current year as it looks to broaden the reach of its platforms
